SCHEMBL843513

SCHEMBL843513

NC(Cc1cccc(O)c1)=NO

nearest known ligand 0.57

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CTBP2 P56545 1/20 0.57
ENPP2 Q13822 1/20 0.53
DRD2 P14416 2/20 0.50
DRD1 P21728 2/20 0.50
TAAR1 Q96RJ0 1/20 0.50
CYP3A4 P08684 2/20 0.48
CYP1A2 P05177 1/20 0.48
PKM P14618 1/20 0.48
ALOX15 P16050 1/20 0.48
NFKB1 P19838 1/20 0.48
MAPK1 P28482 1/20 0.48
LMNA P02545 3/20 0.47
MAPT P10636 2/20 0.47
KMT2A Q03164 1/20 0.47
KDM4E B2RXH2 1/20 0.47
BLM P54132 1/20 0.47
PMP22 Q01453 1/20 0.47
MIF P14174 1/20 0.42
CHRM2 P08172 1/20 0.42
CHRM1 P11229 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL12246382 1.00 CTBP2 (0.57) CTBP2ENPP2DRD2DRD1TAAR1
SCHEMBL836970 0.81 HTR3E (0.65) CTBP2TAAR1CYP3A4HTR3EHTR3B
SCHEMBL17115029 0.81 HTR3E (0.65) CTBP2TAAR1CYP3A4HTR3EHTR3B
SCHEMBL9314494 0.79 ACHE (0.42) CTBP2ENPP2CYP3A4CYP1A2LMNA
SCHEMBL100936 0.79 TAAR1 (0.50) TAAR1MIFHTR3EHTR3BHTR3A
SCHEMBL100935 0.79 TAAR1 (0.50) TAAR1MIFHTR3EHTR3BHTR3A
SCHEMBL27375402 0.79 SIGMAR1 (0.44) CTBP2CYP3A4NFKB1LMNAKMT2A
SCHEMBL1580469 0.79 CTBP2 (0.58) CTBP2TAAR1LMNAHTR3EHTR3B
SCHEMBL1580471 0.79 CTBP2 (0.58) CTBP2TAAR1LMNAHTR3EHTR3B
SCHEMBL5201488 0.79 HIF1A (0.56) CTBP2CYP1A2LMNAMAPTPMP22

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2272848-B1 Xanthine derivatives as selective HM74A agonists GLAXOSMITHKLINE LLC (US) 2012-12-26 EP disclosed
US-8143264-B2 Xanthine derivatives as selective HM74A agonists GLAXOSMITHKLINE LLC (US) 2012-03-27 US disclosed
US-20110257205-A1 XANTHINE DERIVATIVES AS SELECTIVE HM74A AGONISTS GLAXOSMITHKLINE LLC 2011-10-20 US disclosed
US-20110257205-A1 XANTHINE DERIVATIVES AS SELECTIVE HM74A AGONISTS GLAXOSMITHKLINE LLC 2011-10-20 US disclosed
EP-2272848-A1 Xanthine derivatives as selective HM74A agonists Glaxosmithkline LLC (US) 2011-01-12 EP disclosed
US-20100179128-A1 XANTHINE DERIVATIVES AS SELECTIVE HM74A AGONISTS SMITHKLINE BEECHAM CORPORATION 2010-07-15 US disclosed
US-20100179128-A1 XANTHINE DERIVATIVES AS SELECTIVE HM74A AGONISTS SMITHKLINE BEECHAM CORPORATION 2010-07-15 US disclosed
US-20100168122-A1 XANTHINE DERIVATIVES AS SELECTIVE HM74A AGONISTS SMITHKLINE BEECHAM CORPORATION (US) 2010-07-01 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100168122-A1 XANTHINE DERIVATIVES AS SELECTIVE HM74A AGONISTS GPR84, XDH, GPR88 CTBP2 3799/4885ENPP2 144/4885DRD2 1505/4885
US-20110257205-A1 XANTHINE DERIVATIVES AS SELECTIVE HM74A AGONISTS GPR84, GPR88, XDH CTBP2 3081/4885ENPP2 86/4885DRD2 1287/4885
US-20100179128-A1 XANTHINE DERIVATIVES AS SELECTIVE HM74A AGONISTS XDH, GPR84, GPR88 CTBP2 3624/4885ENPP2 122/4885DRD2 1755/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.